Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

1. Sánchez-Muñoz, A.
2. Mendiola, C.
3. Pérez-Ruiz, E.
4. Rodríguez-Sánchez, C.A.
5. Jurado, J.M.
6. Alonso-Carrión, L.
7. Ghanem, I.
8. De Velasco, G.
9. Quero-Blanco, C.
10. Alba, E.